Cardiac allograft vasculopathy (CAV) continues to be a significant risk factor for the recipient's long-term survival following heart transplantation. Our knowledge of its etiology is constantly changing as new imaging techniques provide direct insight into the disease's natural history. CAV identification continues to be difficult since symptoms may be varied or nonexistent. Due to the irreversible nature of the disease, early diagnosis is critical to halting development. Prognostic tools and biomarkers have proliferated as a result of advancements in diagnostic techniques. Simultaneously, pharmaceutical advancements have aided in the amelioration of the disease's progressive progression.

心脏同种异体移植血管病变 (CAV) 仍然是心脏移植后受者长期存活的重要风险因素。随着新的成像技术提供对疾病自然史的直接洞察，我们对其病因的了解不断变化。CAV 识别仍然很困难，因为症状可能多种多样或不存在。由于该疾病的不可逆性，早期诊断对于阻止发展至关重要。由于诊断技术的进步，预后工具和生物标志物已经激增。同时，药物进步有助于改善疾病的进行性进展。